OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
Linus Jönsson, Anders Wimo, Ron Handels, et al.
The Lancet Regional Health - Europe (2023) Vol. 29, pp. 100657-100657
Open Access | Times Cited: 67
Linus Jönsson, Anders Wimo, Ron Handels, et al.
The Lancet Regional Health - Europe (2023) Vol. 29, pp. 100657-100657
Open Access | Times Cited: 67
Showing 1-25 of 67 citing articles:
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Gill Livingston, Jonathan Huntley, Kathy Liu, et al.
The Lancet (2024) Vol. 404, Iss. 10452, pp. 572-628
Closed Access | Times Cited: 480
Gill Livingston, Jonathan Huntley, Kathy Liu, et al.
The Lancet (2024) Vol. 404, Iss. 10452, pp. 572-628
Closed Access | Times Cited: 480
Prescribing in Older People
David G. Le Couteur, Sarah N. Hilmer, Nicholas Glasgow, et al.
(2025), pp. 627-712
Closed Access | Times Cited: 62
David G. Le Couteur, Sarah N. Hilmer, Nicholas Glasgow, et al.
(2025), pp. 627-712
Closed Access | Times Cited: 62
Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis
Danko Jeremic, Juan D. Navarro‐López, Lydia Jiménez‐Díaz
Ageing Research Reviews (2023) Vol. 90, pp. 102012-102012
Closed Access | Times Cited: 41
Danko Jeremic, Juan D. Navarro‐López, Lydia Jiménez‐Díaz
Ageing Research Reviews (2023) Vol. 90, pp. 102012-102012
Closed Access | Times Cited: 41
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
A. Y. Kim, Salman Al Jerdi, Ryan B. MacDonald, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 18
A. Y. Kim, Salman Al Jerdi, Ryan B. MacDonald, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 18
New horizons in the diagnosis and management of Alzheimer’s Disease in older adults
Helena Dolphin, Adam H. Dyer, Laura Morrison, et al.
Age and Ageing (2024) Vol. 53, Iss. 2
Open Access | Times Cited: 12
Helena Dolphin, Adam H. Dyer, Laura Morrison, et al.
Age and Ageing (2024) Vol. 53, Iss. 2
Open Access | Times Cited: 12
Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer’s disease biomarkers
Anna Lidia Wojdaƚa, G. Bellomo, Lorenzo Gaetani, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Anna Lidia Wojdaƚa, G. Bellomo, Lorenzo Gaetani, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Präventive Neurologie – nie zu früh und nie zu spät
E. Schäffer, Ulrike Schara‐Schmidt, Marlena Schnieder
DGNeurologie (2025)
Closed Access | Times Cited: 1
E. Schäffer, Ulrike Schara‐Schmidt, Marlena Schnieder
DGNeurologie (2025)
Closed Access | Times Cited: 1
Lecanemab: More Questions Than Answers!
Upinder Kaur, Jaideep Reddy, Ashutosh Tiwari, et al.
Clinical Drug Investigation (2023) Vol. 44, Iss. 1, pp. 1-10
Closed Access | Times Cited: 17
Upinder Kaur, Jaideep Reddy, Ashutosh Tiwari, et al.
Clinical Drug Investigation (2023) Vol. 44, Iss. 1, pp. 1-10
Closed Access | Times Cited: 17
Current Anti-Amyloid-β Therapy for Alzheimer’s Disease Treatment: From Clinical Research to Nanomedicine
Zixuan Zhao, Yun Liu, Shirong Ruan, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 7825-7845
Open Access | Times Cited: 16
Zixuan Zhao, Yun Liu, Shirong Ruan, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 7825-7845
Open Access | Times Cited: 16
Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation
Anna Dittrich, Eric Westman, Sara Shams, et al.
Neurology (2024) Vol. 102, Iss. 9
Open Access | Times Cited: 7
Anna Dittrich, Eric Westman, Sara Shams, et al.
Neurology (2024) Vol. 102, Iss. 9
Open Access | Times Cited: 7
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer’s Disease. Are We Ready for the New Era?
Roxanna Korologou‐Linden, J. Kalsi, Dimitra Kafetsouli, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 6
Roxanna Korologou‐Linden, J. Kalsi, Dimitra Kafetsouli, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 6
Biological markers of Alzheimer's disease in cerebrospinal fluid: clinical and laboratory comparisons
K. V. Shevtsova, Д. О. Рожков, Д. А. Гришина, et al.
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, Iss. 3, pp. 96-102
Open Access | Times Cited: 6
K. V. Shevtsova, Д. О. Рожков, Д. А. Гришина, et al.
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, Iss. 3, pp. 96-102
Open Access | Times Cited: 6
Effects of a multidomain intervention against cognitive decline on dementia risk profiles — Results from the AgeWell.de trial
Andrea Zülke, Alexander Pabst, Melanie Luppa, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5684-5694
Open Access | Times Cited: 6
Andrea Zülke, Alexander Pabst, Melanie Luppa, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5684-5694
Open Access | Times Cited: 6
People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare
Karin Wahlberg, Bengt Winblad, Amanda Cole, et al.
Journal of Internal Medicine (2023) Vol. 295, Iss. 3, pp. 281-291
Open Access | Times Cited: 14
Karin Wahlberg, Bengt Winblad, Amanda Cole, et al.
Journal of Internal Medicine (2023) Vol. 295, Iss. 3, pp. 281-291
Open Access | Times Cited: 14
Optimising Alzheimer’s Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment
Sandar Aye, Ron Handels, Bengt Winblad, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 5
Sandar Aye, Ron Handels, Bengt Winblad, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 5
Alzheimer's disease: diagnosis and treatment, errors in patient management
В. А. Парфенов, Д. А. Гришина, A. Yu. Tyurina
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, Iss. 2, pp. 95-100
Open Access | Times Cited: 5
В. А. Парфенов, Д. А. Гришина, A. Yu. Tyurina
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, Iss. 2, pp. 95-100
Open Access | Times Cited: 5
Adherence to a lifestyle intervention – just a question of self-efficacy? Analysis of the AgeWell.de-intervention against cognitive decline
Felix Wittmann, Alexander Pabst, Andrea Zülke, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 5
Felix Wittmann, Alexander Pabst, Andrea Zülke, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 5
Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer’s Disease: Recent Advances and Perspectives
Naoyuki Suzuki, T. Hatta, Mana Ito, et al.
Chemical and Pharmaceutical Bulletin (2024) Vol. 72, Iss. 7, pp. 602-609
Open Access | Times Cited: 5
Naoyuki Suzuki, T. Hatta, Mana Ito, et al.
Chemical and Pharmaceutical Bulletin (2024) Vol. 72, Iss. 7, pp. 602-609
Open Access | Times Cited: 5
Public perceptions related to healthcare preparedness to anti-amyloid therapies for Alzheimer’s Disease in Japan
Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 5
Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 5
Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center
Lisa B.E. Shields, H Hust, Susan Cooley, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 4
Lisa B.E. Shields, H Hust, Susan Cooley, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 4
Virginia Memory Project: Using the Healthy Brain Initiative Roadmap to design a statewide dementia registry
Annie Rhodes, Ashley Staton, Evan French, et al.
Alzheimer s & Dementia (2025)
Open Access
Annie Rhodes, Ashley Staton, Evan French, et al.
Alzheimer s & Dementia (2025)
Open Access
The EMA Approves Lecanemab for the Treatment of Alzheimer’s Disease: The Lights and Shadows of This Decision
Angelo Bianchetti, Diego De Leo
GeroPsych (2025)
Closed Access
Angelo Bianchetti, Diego De Leo
GeroPsych (2025)
Closed Access
Nanoscale drug formulations for the treatment of Alzheimer's disease progression
Liu Liqin, Haini He, Bert N. La Du, et al.
RSC Advances (2025) Vol. 15, Iss. 6, pp. 4031-4078
Open Access
Liu Liqin, Haini He, Bert N. La Du, et al.
RSC Advances (2025) Vol. 15, Iss. 6, pp. 4031-4078
Open Access
The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials
Rebekah M. Ahmed, Olivier Piguet, Catherine J. Mummery, et al.
The Lancet Regional Health - Western Pacific (2025) Vol. 55, pp. 101492-101492
Open Access
Rebekah M. Ahmed, Olivier Piguet, Catherine J. Mummery, et al.
The Lancet Regional Health - Western Pacific (2025) Vol. 55, pp. 101492-101492
Open Access
Expanded disease definitions in Alzheimer’s disease and the new era of disease-modifying drugs
Su Jin Yim, Sevil Yaşar, Nancy L. Schoenborn, et al.
BMJ evidence-based medicine (2025), pp. bmjebm-112588
Closed Access
Su Jin Yim, Sevil Yaşar, Nancy L. Schoenborn, et al.
BMJ evidence-based medicine (2025), pp. bmjebm-112588
Closed Access
